ZA200203295B - Sodium-hydrogen exchanger type 1 inhibitor crystals. - Google Patents

Sodium-hydrogen exchanger type 1 inhibitor crystals.

Info

Publication number
ZA200203295B
ZA200203295B ZA200203295A ZA200203295A ZA200203295B ZA 200203295 B ZA200203295 B ZA 200203295B ZA 200203295 A ZA200203295 A ZA 200203295A ZA 200203295 A ZA200203295 A ZA 200203295A ZA 200203295 B ZA200203295 B ZA 200203295B
Authority
ZA
South Africa
Prior art keywords
sodium
exchanger type
hydrogen exchanger
inhibitor crystals
crystals
Prior art date
Application number
ZA200203295A
Other languages
English (en)
Inventor
Lyle Robinson Brostrom
Terrence Joseph Connolly
Zheng Jane Li
Susan Lee Orrill
Bharat Kiritkumar Shah
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of ZA200203295B publication Critical patent/ZA200203295B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Treatment Of Water By Ion Exchange (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ZA200203295A 1999-10-29 2002-04-25 Sodium-hydrogen exchanger type 1 inhibitor crystals. ZA200203295B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16237499P 1999-10-29 1999-10-29

Publications (1)

Publication Number Publication Date
ZA200203295B true ZA200203295B (en) 2003-06-25

Family

ID=22585355

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200203295A ZA200203295B (en) 1999-10-29 2002-04-25 Sodium-hydrogen exchanger type 1 inhibitor crystals.

Country Status (44)

Country Link
EP (1) EP1224179B1 (es)
JP (1) JP2003512455A (es)
KR (1) KR100464526B1 (es)
CN (2) CN1636991A (es)
AP (1) AP2002002493A0 (es)
AR (1) AR029402A1 (es)
AT (1) ATE271047T1 (es)
AU (1) AU778573B2 (es)
BG (1) BG106729A (es)
BR (1) BR0015275A (es)
CA (1) CA2389020A1 (es)
CO (1) CO5271714A1 (es)
CZ (1) CZ20021332A3 (es)
DE (1) DE60012208T2 (es)
DK (1) DK1224179T3 (es)
DZ (1) DZ3463A1 (es)
EA (1) EA004937B1 (es)
EE (1) EE200200227A (es)
ES (1) ES2222923T3 (es)
GE (1) GEP20043222B (es)
GT (1) GT200000180A (es)
HK (1) HK1048472B (es)
HR (1) HRP20020366B1 (es)
HU (1) HUP0204009A3 (es)
IL (1) IL148581A0 (es)
IS (1) IS6302A (es)
MA (1) MA26840A1 (es)
MX (1) MXPA02004358A (es)
NO (1) NO20021821L (es)
NZ (1) NZ517738A (es)
OA (1) OA12080A (es)
PA (1) PA8505501A1 (es)
PE (1) PE20010764A1 (es)
PL (1) PL354869A1 (es)
PT (1) PT1224179E (es)
SI (1) SI1224179T1 (es)
SK (1) SK5312002A3 (es)
SV (1) SV2002000209A (es)
TN (1) TNSN00210A1 (es)
TR (1) TR200201167T2 (es)
UA (1) UA72002C2 (es)
WO (1) WO2001030759A2 (es)
YU (1) YU31502A (es)
ZA (1) ZA200203295B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6441176B1 (en) 1999-10-29 2002-08-27 Pfizer Inc. Method for preparing sodium-hydrogen exchanger type 1 inhibitor
RU2242472C1 (ru) * 2001-01-31 2004-12-20 Пфайзер Продактс Инк. Этаноляты n-(5-циклопропил-1-хинолин-5-ил-1н-пиразол-4-карбонил)гуанидина, способ их получения, фармацевтическая композиция на основе этих соединений и способ получения мезилатной соли n-(5-циклопропил-1-хинолин-5-ил-1н-пиразол-4-карбонил)гуанидина
CA2472342A1 (en) * 2002-01-30 2003-08-07 Pfizer Products Inc. Zoniporide mesylate pharmaceutical compositions and processes for improving solubility of zoniporide
MXPA04008646A (es) * 2002-05-02 2004-12-06 Pfizer Prod Inc Tratamiento para la diabetes y complicaciones diabeticas con inhibidores del nhe-1.

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU739403B2 (en) * 1998-02-27 2001-10-11 Pfizer Products Inc. N-((substituted five-membered di- or triaza diunsaturated ring)carbonyl) guanidine derivatives for the treatment of ischemia

Also Published As

Publication number Publication date
NO20021821D0 (no) 2002-04-18
AP2002002493A0 (en) 2002-06-30
ATE271047T1 (de) 2004-07-15
CZ20021332A3 (cs) 2002-10-16
DE60012208T2 (de) 2005-07-21
HRP20020366A2 (en) 2004-02-29
JP2003512455A (ja) 2003-04-02
OA12080A (en) 2003-08-25
GT200000180A (es) 2002-04-11
CN1384829A (zh) 2002-12-11
SV2002000209A (es) 2002-07-16
BG106729A (bg) 2002-12-29
WO2001030759A3 (en) 2001-09-13
NZ517738A (en) 2005-06-24
HK1048472A1 (en) 2003-04-04
HUP0204009A2 (hu) 2003-03-28
KR20020040918A (ko) 2002-05-30
HK1048472B (zh) 2005-09-16
SI1224179T1 (en) 2004-10-31
CN1636991A (zh) 2005-07-13
CO5271714A1 (es) 2003-04-30
AU778573B2 (en) 2004-12-09
PA8505501A1 (es) 2003-09-05
KR100464526B1 (ko) 2005-01-03
PT1224179E (pt) 2004-10-29
SK5312002A3 (en) 2003-01-09
ES2222923T3 (es) 2005-02-16
PL354869A1 (en) 2004-03-08
BR0015275A (pt) 2002-07-16
UA72002C2 (en) 2005-01-17
YU31502A (sh) 2004-12-31
DK1224179T3 (da) 2004-10-25
EA200200416A1 (ru) 2002-10-31
EE200200227A (et) 2003-06-16
AR029402A1 (es) 2003-06-25
GEP20043222B (en) 2004-04-26
EA004937B1 (ru) 2004-10-28
PE20010764A1 (es) 2001-07-23
MXPA02004358A (es) 2002-11-07
IL148581A0 (en) 2002-09-12
TNSN00210A1 (fr) 2005-11-10
HRP20020366B1 (en) 2005-04-30
AU7441500A (en) 2001-05-08
EP1224179B1 (en) 2004-07-14
MA26840A1 (fr) 2004-12-20
WO2001030759A2 (en) 2001-05-03
NO20021821L (no) 2002-04-18
DE60012208D1 (de) 2004-08-19
IS6302A (is) 2002-03-15
HUP0204009A3 (en) 2004-07-28
DZ3463A1 (fr) 2001-05-03
TR200201167T2 (tr) 2002-08-21
CA2389020A1 (en) 2001-05-03
EP1224179A2 (en) 2002-07-24
CN1205205C (zh) 2005-06-08

Similar Documents

Publication Publication Date Title
TW535893U (en) Heat exchanger
MXPA01013406A (es) Compuestos inhibidores de vla-4.
IL149097A0 (en) 4-carboxyamino-2-ethyl-1,2,3,4-thetrahydroquinoline crystal as cetp inhibitor
AUPP410598A0 (en) Heat exchangers
EP1227974A4 (en) HEAT UMTAUSCHER
GB9919634D0 (en) Heat exchanger
SG78411A1 (en) Filter-heat exchanger
PL342763A1 (en) Matrix metaloprotease inhibitor
EP1136783A4 (en) HEAT EXCHANGER
GB2343643B (en) Heat exchanger
ZA200203295B (en) Sodium-hydrogen exchanger type 1 inhibitor crystals.
DZ3310A1 (fr) Inhibiteurs de l'echangeur sodium-hydrogene de type 1
GB9928207D0 (en) Heat exchanger
ZA994289B (en) Cyclooxygenase inhibitor.
ZA200006007B (en) Method for preparing sodium-hydrogen exchanger type 1 inhibitor.
EP1256771A4 (en) HEAT EXCHANGER
ZA992106B (en) Statin-MMP inhibitor combinations.
GB2338293B (en) Heat exchanger
GB9901538D0 (en) Heat exchanger
GB9803871D0 (en) Heat exchanger
EP1111322A4 (en) HEAT EXCHANGER
AU2175099A (en) Heat exchangers
GB9818707D0 (en) Heat exchanger
GB9826956D0 (en) Heat exchanger
GB9812560D0 (en) Heat exchanger